Thompson Siegel & Walmsley LLC Boosts Stock Position in Catalent, Inc. (NYSE:CTLT)

Thompson Siegel & Walmsley LLC raised its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 31.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 924,305 shares of the company's stock after buying an additional 219,983 shares during the period. Thompson Siegel & Walmsley LLC owned about 0.51% of Catalent worth $41,530,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of CTLT. Gladius Capital Management LP purchased a new stake in shares of Catalent in the 3rd quarter valued at about $28,000. GAMMA Investing LLC acquired a new position in Catalent in the 4th quarter valued at about $33,000. Cary Street Partners Investment Advisory LLC increased its position in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company's stock valued at $35,000 after acquiring an additional 709 shares during the period. Rakuten Securities Inc. acquired a new position in Catalent in the 4th quarter valued at about $46,000. Finally, Federated Hermes Inc. acquired a new position in Catalent in the 4th quarter valued at about $46,000.

Catalent Price Performance

NYSE:CTLT traded down $0.17 during trading hours on Friday, reaching $55.81. 1,604,330 shares of the company traded hands, compared to its average volume of 1,716,717. The firm's 50-day moving average is $56.31 and its 200-day moving average is $49.50. The stock has a market cap of $10.10 billion, a P/E ratio of -9.15, a P/E/G ratio of 6.04 and a beta of 1.18. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.73. Catalent, Inc. has a 1-year low of $31.45 and a 1-year high of $60.20.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. Equities research analysts expect that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on CTLT shares. Barclays boosted their target price on Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a research report on Thursday, January 25th. StockNews.com started coverage on Catalent in a research note on Sunday, May 5th. They set a "sell" rating for the company. Stephens reissued an "equal weight" rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. UBS Group reaffirmed a "neutral" rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Catalent presently has a consensus rating of "Hold" and an average target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.